Innovative Clinical or Translational Science Award
Supports innovative, human-focused clinical or translational research to accelerate new approaches for curing, preventing, or treating Type 1 diabetes.
Funder: American Diabetes Association
Due Dates: April 28, 2026 (Letter of Intent) | June 24, 2026 (Full proposal, invited only)
Funding Amounts: Up to $200,000/year (including 10% indirect costs), max $600,000 over 3 years.
Summary: Supports innovative, human-focused research to advance the cure, prevention, or treatment of Type 1 diabetes by translating discoveries into clinical application.
Key Information: LOI required; only invited applicants may submit full proposals.
Description
This award supports clinical or translational research with novel hypotheses or approaches that directly involve human subjects, samples, or data to advance the cure, prevention, or treatment of Type 1 diabetes (T1D). Projects should accelerate the translation of scientific discoveries into clinical application and demonstrate significant promise for improving outcomes, reducing treatment burden, or transforming management of T1D. The program prioritizes work that can move promising ideas from the laboratory to real-world clinical impact.
